We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TIBSOVO (Servier Laboratories (Aust) Pty Ltd)
Product name
TIBSOVO
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
ivosidenib
Registration type
NCE/NBE
Indication
TIBSOVO is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation after at least one prior line of systemic therapy.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.